14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
32
Design, Synthesis, and Biological Evaluation of Novel Activators of Human Caseinolytic Protease P with a Pyrazololactam Scaffold.

China Pharmaceutical University
36
Harnessing the Magic Methyl Effect: Discovery of CLPP-2068 as a Novel HsClpP Activator for the Treatment of Diffuse Large B-Cell Lymphoma.

Shanghai Institute of Materia Medica
17
ONC201-Derived Tetrahydropyridopyrimidindiones as Powerful ClpP Protease Activators to Tackle Diffuse Midline Glioma.

University of Bari Aldo Moro
42
Structure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Staphylococcus aureus Infection.

Shanghai Institute of Materia Medica
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.

Johann Wolfgang Goethe University
38
Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists.

University of Chinese Academy of Sciences
20
Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.

China Pharmaceutical University
60
Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.

Sichuan University
3
Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.

Sichuan University
2
Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.

Sichuan University
22
The evolution of small molecule enzyme activators.

University of Nebraska
60
Discovery of a Novel Series of Imipridone Compounds as

Sichuan University
23
Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.

Sichuan University
10
De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX.

University of Toronto